Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company is also developing RLYB211, a polyclonal anti-HPA-1a antibody that is in a Phase 1/2 clinical trial for the prevention of FNAIT; RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; and RLYB116, a subcutaneously administered inhibitor of C5 for the treatment of patients with paroxysmal nocturnal hemoglobinuria and generalized myasthenia gravis. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.

CEO

Dr. Martin W. MacKay Ph.D.

Employees

Country

ISIN

US75120L2097

Listings

0 Comments

Share your thoughts

FAQ

What is Rallybio stock price today?▼

The current price of RLYB is $8.43 USD — it has increased by +0.36% in the past 24 hours. Watch Rallybio stock price performance more closely on the chart.

What is Rallybio stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on exchange Rallybio stocks are traded under the ticker RLYB.

Is Rallybio stock price growing?▼

RLYB stock has risen by +2.55% compared to the previous week, the month change is a -21.25% fall, over the last year Rallybio has showed a +89.18% increase.

What is Rallybio market cap?▼

Today Rallybio has the market capitalization of 356.12M

When is the next Rallybio earnings date?▼

Rallybio is going to release the next earnings report on May 12, 2026.

What is Rallybio revenue for the last year?▼

Rallybio revenue for the last year amounts to 1.27M USD.

What is Rallybio net income for the last year?▼

RLYB net income for the last year is -115.55M USD.

How many employees does Rallybio have?▼

As of April 03, 2026, the company has 25 employees.

In which sector is Rallybio located?▼

Rallybio operates in the Health Care sector.

When did Rallybio complete a stock split?▼

The last stock split for Rallybio was on February 06, 2026 with a ratio of 1:8.

Where is Rallybio headquartered?▼

Rallybio is headquartered in New Haven, US.